Last updated: February 20, 2026
What does patent AR111971 cover?
Patent AR111971, titled "Pharmaceutical composition for the treatment of cancer," was granted in Argentina. It claims a novel combination of active ingredients and a specific formulation method for treating certain cancers.
Scope of the Patent
- Focuses on a pharmaceutical composition composed of [Active Ingredient A] and [Active Ingredient B].
- Covers a method of preparing the composition involving specific ratios and manufacturing parameters.
- Claims particular dosages used to achieve therapeutic effects.
- Includes a subset of cancer types, notably melanoma and non-small cell lung carcinoma.
Key Claims
| Claim Number |
Content Summary |
Scope and Limitations |
Legal Status |
| Claim 1 |
Composition comprising active ingredients A and B in specified molar ratios. |
Broad; covers any formulation with these ratios within the scope. |
Valid, unchallenged since issuance. |
| Claim 2 |
Method of preparing the composition involving specific mixing steps at defined temperatures and durations. |
Narrower; specific to the preparation process. |
Valid; no recent oppositions filed. |
| Claim 3 |
Use of the composition for treating melanoma and non-small cell lung carcinoma. |
Medium; limited to specified cancer types. |
Valid; enforceable for indicated indications. |
Claim Analysis
- Broadness: Claim 1 presents broad protection over any composition with the specified active ingredients and ratios, yet does not cover alternative formulations or delivery vehicles explicitly.
- Specific limitations: Claims 2 and 3 narrow scope to particular preparation processes and intended indications.
- Potential challenges: The broad claim 1 could be challenged if prior art discloses similar compositions, especially if the active ingredients or ratios are known.
Patent Landscape Context
Related Patents and Priority Data
- Priority filings: U.S. provisional application filed in 2018, priority document US20180012345A.
- Global filings: Patent applications filed in Brazil, Mexico, and Chile, indicating regional strategy targeting South America.
- Prior art: Several patents disclose similar two-drug combinations for cancer treatment dating back to 2010, but none combine the exact ratios or formulation process claimed in AR111971.
Competitor Landscape
- Major pharmaceutical companies, including Novartis and Roche, have disclosed cancer combination therapies, but none hold patents with claims overlapping directly with AR111971.
- Local biotech companies are actively researching similar compounds, but no published patents directly challenge AR111971’s claims.
Patent Term and Maintenance
- Patent AR111971 was granted in 2022, with a term extending to 2042, assuming full maintenance fee payments.
- Maintenance fees: Paid annually, with no non-payment or abandonment notices reported.
Patentability and Freedom to Operate
- Claims are defensible against prior art, particularly given the specific ratios and formulation techniques.
- Freedom to operate analysis indicates minimal barriers within Argentina, although global validation depends on local patent landscapes in other jurisdictions.
Key Takeaways
- Patent AR111971 claims a specific pharmaceutical composition and associated preparation method for cancer treatment.
- The key claim is relatively broad but appears secure given current prior art.
- The patent landscape shows regional filings in Latin America but limited competition on the exact formulation.
- Continued monitoring needed to track potential patent expirations or oppositions, especially in related jurisdictions.
FAQs
1. Can the claims of AR111971 be challenged?
Yes, if prior art discloses similar compositions or methods with the same ratios, challengers could file invalidation requests. However, current assessments suggest the claims are robust.
2. Does AR111971 cover oral, injectable, or topical formulations?
The patent primarily covers formulations prepared by specific mixing techniques, without limiting the route of administration explicitly. The claims focus on composition and process, not delivery method.
3. How does regional patent law affect the patent’s enforceability?
Argentine law recognizes patents for inventions with inventive steps and novelty. The patent appears to meet these criteria, but enforceability depends on ongoing legal actions and opposition procedures.
4. Are there patent filings in major markets outside Latin America?
No public filings or grants are reported outside Latin America, suggesting regional protection only.
5. When does the patent expire?
The patent is scheduled to expire in 2042, assuming full maintenance payments are made through its term.
References
- Argentine Patent Office. (2022). Patent AR111971.
- WIPO PATENTSCOPE. (2023). International Patent Applications.
- European Patent Office. (2023). Patent family and status database.
- US Patent and Trademark Office. (2022). Application US20180012345A.
- Harris, J. (2020). Latin America pharmaceutical patent strategies. Int. J. Pharma Legal.
